James Signorovitch

Vice President

James Signorovitch

Boston

Education

Ph.D., biostatistics, Harvard University; B.A., biology, Cornell University 

Summary of Experience

Dr. Signorovitch advises pharmaceutical and medical device companies, drawing on his research on the value of health care products. He has broad experience with the development and implementation of health economics and outcomes research strategies in a number of therapeutic areas and disease states, including cardiovascular medicine, diabetes, oncology, immunology, and infectious diseases. Dr. Signorovitch specializes in the development and application of new research methods for health data, including electronic medical records, chart reviews, surveys, registries, and administrative claims. He has designed and analyzed clinical trials, performed benefit-risk analyses, developed health economic models, validated quality-of-life instruments, investigated the impacts of formulary policy changes, built predictive models for health risks, and led the creation of software to support medical decision making. Dr. Signorovitch’s research has been published in peer-reviewed journals and presented at clinical and economic research conferences, as well as to health care payers to inform formulary decisions. Prior to joining Analysis Group, Dr. Signorovitch was a research fellow at the Harvard-MIT Division of Health Sciences and Technology.

Selected Publishing

  • Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe

    J Med Econ. 2014 Dec; 17(12):837-45
    2014

    Campone M, Yang H, Faust E, Kageleiry A, Signorovitch JE, Zhang J, Gao H.

      View abstract
    Health Care
  • Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment

    Br J Dermatol. 2014 Dec; 171(6):1434-42
    2014

    Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, Gu Y, Wang K, Mulani P, Sundaram M 

      View abstract
    Health Care
  • Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review

    Curr Med Res Opin. 2014 Apr; 30(4):537-45
    2014

    Wong MK, Yang H, Signorovitch JE, Wang X, Liu Z, Liu NS, Qi CZ, George DJ.

      View abstract
    Health Care
  • Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012

    Curr Med Res Opin. 2014 Aug;30(8):1537-45
    2014

    Swallow E, Zhang J, Thomason D, Tan RD, Kageleiry A, Signorovitch J

      View abstract
    Health Care
  • Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease

    Eur J Endocrinol. 2014 Jul; 171(1):89-98
    2014

    Webb SM, Ware JE, Forsythe A, Yang M, Badia X, Nelson LM, Signorovitch JE, McLeod L, Maldonado M, Zgliczynski W, de Block C, Portocarrero-Ortiz L, Gadelha M 

      View abstract
    Health Care
  • Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies

    PLoS One. 2014 Dec 10;9(12):e114264
    2014

    Heng DY, Signorovitch J, Swallow E, Li N, Zhong Y, Qin P, Zhuo DY, Wang X, Park J, Stergiopoulos S, Kollmannsberger C

      View abstract
    Health Care
  • Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison

    Exp Hematol Oncol. 2013 Dec 6;2(1):32
    2013

    Signorovitch J, Swallow E, Kantor E, Wang X, Klimovsky J, Haas T, Devine B, Metrakos P 

      View abstract
    Health Care
  • Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs

    Diabetes, Obesity and Metabolism, November 2012
    2012

    Signorovitch J, Macaulay D, Diener M, Yan Y, Wu EQ, Gruenberger J, Frier B

      View abstract
    Health Care
  • Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution

    Pediatr Pulmonol. 2012 Jan;47(1):44-52. doi: 10.1002/ppul.21521. Epub 2011 Aug 3.
    2012

    Sawicki G, Signorovitch J, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L

      View abstract
    Health Care
  • Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity

    J Med Econ. 2012; 15(6):1078-87
    2012

    Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ.

      View abstract
    Health Care
  • The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate-severe psoriasis

    JAAD. 2011 May 24
    2011

    Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM

      View abstract
    Health Care
  • Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life

    Clin Drug Investig. 2011; 31(1):51-60
    2011

    Papp K, Signorovitch J, Ramakrishnan K, Yu AP, Gupta S, Bao Y, Mulani P

      View abstract
    Health Care
  • Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials

    Curr Med Res Opin. 2011 Jun;27(6):1263-71. Epub 2011 Apr 28
    2011

    Signorovitch J, Wu EQ, Betts K, Parikh K, Kantor E, Guo A, Bollu V, Williams D, Wei L, DeAngelo D

      View abstract
    Health Care
  • Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors

    Curr Med Res Opin. 2011 Jun;27(6):1089-96. Epub 2011 Mar 28. Erratum in: Curr Med Res Opin. 2011 Sep;27(9):1708.
    2011

    Signorovitch J, Ramakrishnan K, Ben-Hamadi R, Yu AP, Wu EQ, Dworak H, Erder M

      View abstract
    Health Care
  • Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes: a matching-adjusted indirect comparison of randomized trials

    Clin Drug Investig. 2011;31(9):665-74. doi: 10.2165/11592490-000000000-00000.
    2011

    Signorovitch J, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger J

      View abstract
    Health Care
  • Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials

    Dermatology. 2010;220(1):1-7. Epub 2009 Nov 19
    2010

    Mease P,  Signorovitch J, Yu A,  Wu E, Gupta S, Bao Y, Mulani P

      View abstract
    Epidemiology & BiostatisticsHealth Care
  • The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial

    J Am Acad Dermatol. 2010 May;62(5):812-8. Epub 2010 Mar 9
    2010

    Menter A, Augustin M,  Signorovitch J, Yu A,  Wu E, Gupta S, Bao Y, Mulani P

      View abstract
    Epidemiology & BiostatisticsHealth Care
  • Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment

    Pharmacoeconomics. 2010 Oct 1;28(10):935-45. doi: 10.2165/11538370-000000000-00000
    2010

    Signorovitch JWu E, Yu A, Gerrits C, Kantor E, Bao Y, Gupta S, Mulani P

      View abstract
    Health Care
  • Benefit-risk analysis of adalimumab vs methotrexate and placebo in the treatment of moderate to severe psoriasis

    J Am Acad Dermatol. 2010 Oct 6. [Epub ahead of print]
    2010

    Reich K,  Signorovitch J, Ramakrishnan K, Yu A, Wu EQ, Gupta S, Bao Y, Mulani P

      View abstract
    Epidemiology & BiostatisticsHealth Care
  • Cardiovascular and Economic Outcomes After Initiation of Atorvastatin versus Simvastatin in an Employed Population Stratified by Cardiovascular Risk

    Am J Ther. 2010 Aug 27
    2010

    Simpson R Jr, Signorovitch J, Ramakrishnan K, Ivanova JBirnbaum H, Kuznik A

      View abstract
    Epidemiology & BiostatisticsHealth Care
  • Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin

    Curr Med Res Opin. 2010 Feb; 26(2):355-63
    2010

    Signorovitch JDuh M, Sengupta A, Gu A, Grant R, Raut M, Mody S, Schein J, Fisher A, Ng D

      View abstract
    Epidemiology & BiostatisticsHealth Care
  • Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension

    Curr Med Res Opin. 2010 Apr; 26(4):849-60
    2010

    Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH

      View abstract
    Health Care
  • Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population

    Mayo Clin Proc. 2009 Dec;84(12):1065-72
    2009

    Simpson R Jr,  Signorovitch JBirnbaum HIvanova J, Connolly C, Kidolezi Y, Kuznik A

      View abstract
    Epidemiology & BiostatisticsHealth Care
James Signorovitch
Practices